← Leaderboards
David Michael Schuster
Emory University
$5,425,562
Attributed
$8,028,218
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $820.6K · FY2007–23$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$8,028,218 · 5
By mechanism
R01$6,846,743 · 3
P50$819,057 · 1
R21$362,418 · 1
Top collaborators
- Ashesh Jani10 shared
Most similar at Emory University
Same institution · by research overlap
- Ashesh Jani$3,084,487
- Mark Myron Goodman$10,198,938
- Sunil Singhal$10,554,167
- Xiaofeng Yang$4,796,965
- Scott D. Boden$2,466,637
Others in their field
Top investigators on “Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$257,543,614
- Charles A Coltman · Southwest Oncology Group$181,133,593
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Larry Arthur$62,719,328
- William J. Blot · Vanderbilt University$62,640,427
- Walter John Curran · Thomas Jefferson University$60,981,384
Research focus
ProstateMalignant Neoplasm Of ProstateImageRadiotracerPositron-Emission TomographyBaseProstate CarcinomaStructureTumorDetectionUptakeBiopsyPathologicTissuesRadiation TherapyCancer PatientDoseProstatectomyCarboxylic AcidsBedsRecurrenceTreatment PlanningStagingAmino Acid Transporter
Grant awards (22)
Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes$515,432
R01 · FY2023 · CA
Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes$611,964
R01 · FY2022 · CA
Improved staging of lobular breast cancer with novel amino acid metabolic and tumor neovasculature receptor imaging.$193,293
R21 · FY2022 · CA · contact PI
Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes$651,443
R01 · FY2021 · CA
Improved staging of lobular breast cancer with novel amino acid metabolic and tumor neovasculature receptor imaging.$169,125
R21 · FY2021 · CA · contact PI
Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes$665,965
R01 · FY2020 · CA
Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes$629,419
R01 · FY2019 · CA
Molecular Imaging with FACBC PET-CT to Improve Post prostatectomy Radiotherapy$400,052
R01 · FY2016 · CA
Molecular Imaging with FACBC PET-CT to Improve Post prostatectomy Radiotherapy$400,052
R01 · FY2015 · CA
Molecular Imaging with FACBC PET-CT to Improve Post prostatectomy Radiotherapy$449,629
R01 · FY2014 · CA
Molecular Imaging with FACBC PET-CT to Improve Post prostatectomy Radiotherapy$427,048
R01 · FY2013 · CA
Molecular Imaging with FACBC PET-CT to Improve Post prostatectomy Radiotherapy$454,308
R01 · FY2012 · CA
Anti-[18 F] FACBC PET-CT for Characterization of Primary Prostate Carcinoma$108,365
P50 · FY2012 · CA · contact PI
18F-FACBC PET-CT for the Detection and Staging of Recurrent Prostate Carcinoma$234,999
R01 · FY2011 · CA · contact PI
Anti-[18 F] FACBC PET-CT for Characterization of Primary Prostate Carcinoma$154,088
P50 · FY2011 · CA · contact PI
18F-FACBC PET-CT for the Detection and Staging of Recurrent Prostate Carcinoma$349,147
R01 · FY2010 · CA · contact PI
Anti-[18 F] FACBC PET-CT for Characterization of Primary Prostate Carcinoma$193,300
P50 · FY2010 · CA · contact PI
18F-FACBC PET-CT for the Detection and Staging of Recurrent Prostate Carcinoma$343,987
R01 · FY2009 · CA · contact PI
Anti-[18 F] FACBC PET-CT for Characterization of Primary Prostate Carcinoma$223,120
P50 · FY2009 · CA · contact PI
18F-FACBC PET-CT for the Detection and Staging of Recurrent Prostate Carcinoma$359,596
R01 · FY2008 · CA · contact PI
Anti-[18 F] FACBC PET-CT for Characterization of Primary Prostate Carcinoma$140,184
P50 · FY2008 · CA · contact PI
18F-FACBC PET-CT for the Detection and Staging of Recurrent Prostate Carcinoma$353,702
R01 · FY2007 · CA · contact PI